Croda Share Discussion Threads

[wad collector] 30/7/2024 22:19

Chart not looking so pretty now, with HY results giving some negative numbers but some positive words. The interim divi of 47p is sustained but now barely covered by the 57p EPS.
Going to be a long way back up I fear.

[wad collector] 12/7/2024 21:42

Yes that concept can only be used for a finite period. But ultimately they are in a reasonable niche with multiple products, they will prosper again eventually if they maintain market share.
They are still double what they were a decade ago. Unimpressive but steady, if we ignore the covid bonus.

free stock charts from uk.advfn.com

[grechen] 05/7/2024 11:07

They have said several times over last 2 years that customers have been running down their stocks in uncertain economic climate. The time has got to come when they need to re-stock and sales figures improve.

[uhound] 03/7/2024 17:43

Depends on how the market values the company.

Based on earnings and assets £30 per share?

EPS has declined a lot over the last few years, but perhaps we may se a recovery this year?

[commuter10] 01/7/2024 12:32

How low can it go? I'd wait until Friday after the election to buy.

[stoopid] 01/7/2024 10:42

Fair point.....

[scobak] 01/7/2024 09:22

I look at the price and the fundamentals.
Currently £39.20 and falling.
Historically £39.52 is a good price but perhaps not a really good entry point.

[stoopid] 29/6/2024 10:56

Bought in at 3952. With the RSI below 30 and the lowest share price in around 5 years I hope it's a good entry point....

[stoopid] 28/6/2024 11:00

But only for an hour or so and has already bounces back above.Been watching CRDA foe a while now and wondering if now is the right time to buy in?

[uncle_sam] 28/6/2024 09:18

Broken 3 year support, circa 4000.

[wad collector] 24/4/2024 20:48

Q1 sales figures not impressed the market today.

[wad collector] 15/4/2024 09:50

Xd this week.

[wad collector] 29/2/2024 14:39

Everything down except debt! Surprised that share price has gone up, presumably worse was expected.

[battyliveson] 27/2/2024 07:49

Poor numbers, but probably expected given share price movements in last couple of years.

I think a fair value for croda is around £4.4 to £5.6bn, so will wait before I get back in.

B

[wad collector] 05/2/2024 16:38

Bouncing off £50 atm , maybe the worse is behind CRDA now, this is an industry with high barriers to entry , but still a long way back to the heady £100 days of 2021.

[wad collector] 14/12/2023 16:50

Thanks for that, the sharp share price rise suggests an impressive influence of the broker!

[smcni1968] 14/12/2023 14:02

Croda a long C-road to recoveryOperationally, a load C-road to recovery. We reduce Croda estimates c. 12% for FY24 and our target price to £53. In Consumer Care, we expect a sequential improvement in destocking; however, as demonstrated above, the overhang of inventories at HPC customers remains into the start of FY24. With a realignment of customer inventories globally still ongoing (esp. in Asia) and slower growth from large-cap customers more generally, the snap-back will not be immediate. This has raised and continues to raise debate around the defensiveness and quality of Croda's Consumer Care portfolio, given volume declines well in excess of even its lowest-quality peers, despite the cushioning from substantial growth in Iberchem.From an earnings perspective, even with stabilising volumes y/y, earnings remain impacted by operating deleverage and high-priced inventories. With it clear Ag end markets are unlikely to recover until H2. While volumes seem to be turning (Actives up y/y, Beauty Effects still negative) and despite work on inventories, we are not completely out of the woods, with inventories still above average. Risk therefore remains that the boost in volumes through September/October is short-lived near term, and thus, the outlook remains weak. We expect a weak 1H24 - essentially reflecting the 2H run rates, with a more meaningful improvement coming through as the year progresses.Strategically, poised but not yet able to catalyse growth given operational challenges. In the mid-term, Croda's less levered balance sheet than peers provides optionality from an acquisition perspective, with ND/EBITDA still c1x (at current EBITDA levels c1.4x). In the near term, the ability to acquire businesses remains constrained, with the attractive IFF Lucas Meyer assets too expensive, given current uncertainties in outlook and in managing the core business. Overall, that high-multiple stocks can get these deals executed at these multiples is another affirmation that multiples in the sector remain too high. For Croda to participate further in acquisitions, we believe a meaningful decline in industry multiples must be evident in asset prices.

[1retroz] 14/12/2023 08:48

Nice rise this morning. Apparently a report issued by Jefferies - has anyone seen yhe report?

[wad collector] 06/12/2023 16:38

Looks like the nadir has passed. Long way back up though...

[glennrcharles] 14/11/2023 14:44

I wonder whether the director's purchase is linked to the positive test results expected from the skinbiotix lysate expected soon.

[fuji99] 23/10/2023 09:13

40% drop since the start of 2022.

[arja] 09/10/2023 14:31

got close to the 4170 chart support after the bad news but maybe it has bottomed at that point . Any trader quick on his or feet will have made heaps today if buying close to low point .

[pugugly] 09/10/2023 13:40

Woops - Croda cuts profit guidance as clients focus on reducing stockpiles
Croda now anticipates adjusted pre-tax profits of £300m to £320m this year
It is the second time in recent months that the firm has cut its profit outlook
The group's shares were the FTSE 100's worst performer on Monday morning
By HARRY WISE

Croda International has slashed its annual earnings outlook following a weaker-than-expected performance as its customers continued to destock their inventories.

The speciality chemicals provider now anticipates reporting adjusted pre-tax profits of £300million to £320million this year, down from previous guidance of between £370million and £400million.

It is the second profit warning the FTES 100 firm has delivered this year after declaring in June that earnings would be weaker than the £440million forecast by analysts.